Russia launches another round of airstrikes in Syria. In Afghanistan, fighting with the Taliban continues in Kunduz. And a Palestinian flag flies at the U.N. for the first time. A panel of journalists joins guest host Melissa Block for analysis of the week's top international news stories.
Since Tuesday’s election, many Republicans have called for a frank reassessment of what it means to be a member of the GOP. As one Republican strategist put it, “Our party needs to realize that it’s too old and too white and too male and it needs to figure out how to catch up with the demographics of the country before it’s too late.” Diane and Republican analysts discuss the identity and future of the GOP.
- David Winston Republican strategist, president of the Winston Group and CBS News consultant. He has served as an adviser to the House and Senate Republican leadership for more than a decade.
- Leslie Sanchez Republican-affiliated consultant, founder and CEO of Impacto Group LLC, and author of "Los Republicanos: Why Hispanics and Republicans Need Each Other.”
- Henry Olsen vice president of the American Enterprise Institute.
- Matt Kibbe president and CEO of FreedomWorks, and author of "Hostile Takeover: Resisting Centralized Government's Stranglehold on America."
Most Recent Shows
Nine people and a gunman are dead after a shooting at an Oregon community college. Bernie Sanders narrows the fundraising gap with Hillary Clinton in the last quarter. And Congress avoids a government shutdown – for now. A panel of journalists joins guest host Melissa Block of NPR News for analysis of the week's top national news stories.
Russian President Putin is widely popular in Russia, despite his ruthless reputation abroad. A former Moscow bureau chief for The New York Times explains how Putin rose from obscurity to become one of the world’s most powerful and enigmatic leaders.
The owner of a drug company has come under fire for dramatically raising the price of medicine that fights deadly infections. And the prices of some heart medications have also spiked. We look at the renewed controversy over high drug prices in the U.S.